Compare · ONCY vs PBYI
ONCY vs PBYI
Side-by-side comparison of Oncolytics Biotech Inc. (ONCY) and Puma Biotechnology Inc (PBYI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ONCY and PBYI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PBYI is the larger of the two at $409.2M, about 3.6x ONCY ($112.3M).
- Over the past year, ONCY is up 40.7% and PBYI is up 139.5% - PBYI leads by 98.9 points.
- ONCY has been more active in the news (22 items in the past 4 weeks vs 10 for PBYI).
- PBYI has more recent analyst coverage (4 ratings vs 2 for ONCY).
- Company
- Oncolytics Biotech Inc.
- Puma Biotechnology Inc
- Price
- $0.94+1.56%
- $8.06+5.08%
- Market cap
- $112.3M
- $409.2M
- 1M return
- +17.92%
- +14.33%
- 1Y return
- +40.67%
- +139.52%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 22
- 10
- Recent ratings
- 2
- 4
Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Latest ONCY
- Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
- SEC Form 3 filed by new insider Mcadory John Bearden
- SEC Form 4 filed by Director Pisano Wayne
- SEC Form 4 filed by Director Rigby Jonathan
- SEC Form 4 filed by Director Holtham Angela
- SEC Form 4 filed by Director Parsons James T.
- SEC Form 4 filed by Chief Business Officer Aromando Andrew
- SEC Form 4 filed by Chief Financial Officer Look Kirk
- SEC Form 4 filed by Chief Executive Officer Kelly Jared
Latest PBYI
- Puma Biotechnology Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wilson Troy Edward was granted 27,000 shares and sold $77,748 worth of shares (10,800 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 59,750 units (SEC Form 4)
- Director Stuglik Brian M was granted 27,000 shares and sold $58,311 worth of shares (8,100 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 20% to 113,858 units (SEC Form 4)
- Director Senderowicz Adrian sold $194,311 worth of shares (27,000 units at $7.20) as part of a pre-agreed trading plan and was granted 27,000 shares (SEC Form 4)
- Director Miller Michael Patrick was granted 27,000 shares, increasing direct ownership by 50% to 81,000 units (SEC Form 4)
- Director Moyes Jay M was granted 27,000 shares and sold $158,796 worth of shares (22,000 units at $7.22) as part of a pre-agreed trading plan, increasing direct ownership by 9% to 58,322 units (SEC Form 4)
- Director Dorval Allison was granted 27,000 shares and sold $83,579 worth of shares (11,610 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 20% to 90,780 units (SEC Form 4)
- Director Cesano Alessandra was granted 27,000 shares, increasing direct ownership by 65% to 68,850 units (SEC Form 4)
- SEC Form 144 filed by Puma Biotechnology Inc
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)